O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma by Ma, S et al.
O
6-methylguanine-DNA-methyltransferase expression and gene
polymorphisms in relation to chemotherapeutic response in
metastatic melanoma
SM a
1, S Egyha ´zi
1, T Ueno
1, C Lindholm
2, EL Kreklau
3, U Stierner
4, U Ringborg
1 and J Hansson*,1
1Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden;
2Department of Oncology,
Ryhov County Hospital, Jo ¨nko ¨ping, Sweden;
3Indiana University Cancer Centre, Department of Pharmacology/Toxicology, Indiana University School of
Medicine, Indianapolis, IN, USA;
4Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
In a retrospective study, O
6-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry
using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug
therapy or as part of combination chemotherapy with DTIC–vindesine or DTIC–vindesine–cisplatin. The correlation of MGMT
expression levels with clinical response to chemotherapy was investigated in 79 patients with metastatic melanoma. There was an
inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy (P¼0.05). Polymorphisms in
the coding region of the MGMT gene were also investigated in tumours from 52 melanoma patients by PCR/SSCP and nucleotide
sequence analyses. Single-nucleotide polymorphisms (SNPs) in exon 3 (L53L and L84F) and in exon 5 (I143V/K178R) were identified.
There were no differences in the frequencies of these polymorphisms between these melanoma patients and patients with familial
melanoma or healthy Swedish individuals. Functional analysis of variants MGMT-I143V and -I143V/K178R was performed by in vitro
mutagenesis in Escherichia coli. There was no evidence that these variants decreased the MGMT DNA repair activity compared to the
wild-type protein. All melanoma patients with the MGMT 53/84 polymorphism except one had tumours with high MGMT
expression. There was no significant correlation between any of the MGMT polymorphisms and clinical response to chemotherapy,
although an indication of a lower response rate in patients with SNPs in exon 5 was obtained. Thus, MGMT expression appears to be
more related to response to chemotherapy than MGMT polymorphisms in patients with metastatic melanoma.
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In recent decades, cutaneous malignant melanoma has shown a
marked increase in incidence in developed countries with
Caucasian populations. Disseminated melanoma is known to be
an incurable disease that responds poorly to chemotherapy due to
resistance to antitumour drugs. No regimen, so far, has demon-
strated improved survival compared to single-agent therapy with
dacarbazine (DTIC) in disseminated melanoma (Serrone et al,
2000). Thus, new insights into the mechanisms of resistance to
chemotherapeutic drugs are essential, since they may lead to
development of predictive tests that can identify individuals with
tumours sensitive to a specific agent, as well as to the development
of strategies to circumvent drug resistance, thereby improving the
results of therapy.
Dacarbazine, which is commonly used in chemotherapy of
metastatic melanoma, is a methylating cytostatic drug which
produces O
6-methylguanine (O
6-mG). O
6-methylguanine in DNA
mis-pairs with thymine during DNA synthesis and initiates
repeated ineffective cycles of DNA mismatch repair (MMR). This
results in generation of DNA strand breaks, which may induce
apoptotic signal transduction and thus kill the tumour cells (Pegg,
1990; Karran and Bignami, 1994).
O
6-methylguanine-DNA-methyltransferase (MGMT) is a DNA
repair protein which can transfer the methyl group from the O
6-
atom in the guanine base to an internal cysteine residue at codon
145 in the protein. This protein thus removes the primary
cytotoxic lesion induced by O
6-methylating agents, such as DTIC,
thereby preventing cytotoxicity and causing resistance to the drug.
O
6-methylguanine-DNA-methyltransferase thus confers resistance
to certain alkylating antitumour agents such as the methylating
drugs DTIC and temozolomide (TMZ) in cultured tumour cells
(Pegg, 1990, 2000), including melanoma cells (Lage et al, 1999). O
6-
methylguanine-DNA-methyltransferase knockout mice have been
shown to be sensitive to the effects of chemotherapeutic alkylating
agents (Glassner et al, 1999). Clinical studies of the relationship
between MGMT levels and response to chemotherapy have given
differing results in different tumour types (Friedman et al, 1998b;
Middleton et al, 1998; Park et al, 2002). To some extent these
differences may depend on the various techniques used to assay
MGMT and tumour heterogeneity. We have previously shown that
MGMT expression varies considerably in different melanoma
tumours, both between patients and in the same patient (Egyha ´zi
et al, 1997; Ma et al, 2002). Received 28 October 2002; revised 6 June 2003; accepted 25 July 2003
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sSingle-nucleotide polymorphisms (SNPs) represent an impor-
tant class of genetic variants, and SNPs in genes encoding the
enzymes responsible for drug metabolism are under intense
investigation to define possible molecular differences of impor-
tance for drug metabolism and response to pharmacologic therapy.
Single nucleotide polymorphisms in the MGMT gene can have
effects on the MGMT activity (Hazra et al, 1997) or on sensitivity
to the MGMT inhibitor O
6-benzylguanine (O
6-BG) (Edara et al,
1996; Pegg et al, 1998) and might therefore have an effect on
clinical response to DTIC-based chemotherapy in melanoma.
In a previous study (Egyha ´zi et al,2 0 0 2 ) ,w ei n v e s t i g a t e dS N P si n
the promoter and coding regions of the MGMT gene in blood from
patients with familial melanoma and healthy Swedish individuals. In
total, 11 SNPs of the MGMT gene were identified in that study,
including variants at codons 53 and 84 in exon 3, and at codons 143,
178 and 197 in exon 5. Codon 143 is very close to the MGMT active
site cysteine-145, and the polymorphism at codon 143 appears to be
linked to the codon 178 polymorphism. Owing to its location, it is
possible that the 143 variant itself, or in combination with the 178
variant, might have an effect on MGMT activity.
In a previous study, we evaluated MGMT expression in human
melanoma metastases, and saw a tendency of lower MGMT
expression in responders to DTIC-based chemotherapy compared
with nonresponders (Ma et al, 2002). In the present study, MGMT
expression has been analysed in additional tumour samples to
further investigate whether MGMT may be a drug resistance factor to
DTIC-based chemotherapy in melanoma. Single nucleotide poly-
morphisms in the coding regions of the MGMT gene have also been
analysed to investigate the possible relevance of MGMT SNPs for
response to chemotherapy in melanoma patients. Functional analysis
of the codon 143 variant and double variant 143/178 of MGMT was
also performed by in vitro mutagenesis in Escherichia coli.
MATERIAL AND METHODS
Patients and tumour biopsies
Tumour biopsies from 79 patients with metastatic melanoma were
included in this study, of whom 65 were included in our earlier
study (Ma et al, 2002). Of these patients, 73 had been treated at
Radiumhemmet, Karolinska Hospital with DTIC as single drug or
had participated in a randomised phase III trial comparing DTIC
in combination with vindesine to a three-drug regimen of DTIC,
vindesine and cisplatin (Jungnelius et al, 1998). In addition, six
patients had received chemotherapy with DTIC alone outside
Karolinska Hospital (four patients from Ryhov Hospital in
Jo ¨nko ¨ping, one from Sahlgrenska University Hospital in Gothen-
burg and one from Va ¨xjo ¨ Central Hospital). Clinical response data
were obtained from patient records. WHO criteria for clinical
response were used for classification in the categories complete
response (CR), partial response (PR), stable disease (SD) and
progressive disease (PD). Patients with CR and PR were grouped
together as responders (R) and those with SD and PD as
nonresponders (NR).
A total of 110 biopsies from melanoma metastases obtained
before chemotherapy from 79 patients were investigated. In 20 of
the patients, more than one metastasis was analysed. There were 47
male and 32 female patients with a median age of 58 years (range
22–83 years). In the whole group of 79 patients, 20 were classified
as R and 59 as NR. Of the 53 patients who had received
chemotherapy with DTIC alone, 12 patients were classified as R
and 41 as NR.
Immunohistochemistry
Immunohistochemical staining for MGMT was performed in the
same manner as described previously (Ma et al, 2002). Briefly,
monoclonal human anti-MGMT antibody (20mgml
 1, clone
MT3.1, Chemicon International, Inc., Temecula, CA, USA) was
used in the formalin-fixed, paraffin-embedded tissues, with mouse
IgG1 as negative control. The tissue sections were incubated with a
biotinylated universal second antibody and streptavidin/perox-
idase complex (Vector Laboratories, Inc., Burlingame, CA, USA),
exposed to 3,3-diaminobenzidine tetrahydrochloride (DAB) for
chromogen development, and counterstained with haematoxylin.
For each biopsy, the whole slide was examined and the overall
proportion of MGMT staining tumour cells was estimated
regardless of intensity of staining. For comparison with clinical
data on treatment outcome, the tumour biopsies were divided into
two groups with o50% and X50% tumour cells staining positively
for MGMT. In cases where more than one tumour from the same
individual had been analysed, with different outcome with respect
to the proportion of MGMT-positive tumour cells, the tumour with
the highest percentage of MGMT-positive cells was used for the
comparison with outcome of clinical treatment. Statistical analyses
were performed with the w
2 test or Fisher’s exact two-tailed test.
Genetic polymorphism analysis
DNA was extracted from the paraffin-embedded biopsies of
melanoma metastases. The tumour cells were carefully micro-
dissected from the selected tumour area with a scalpel from two or
three 20mm sections guided by haematoxylin- and eosin-stained
slides, since this material was also used to screen for somatic
mutations in melanoma cells as part of another project. After
deparaffinisation, the scraped tissue was suspended in digestion
buffer containing 10mM Tris-HCl, pH 8.3, 1mM EDTA, 0.5%
Tween-20 and 50mgml
 1 proteinase K and incubated overnight at
561C in a shaker. DNA was purified by the Wizard DNA clean-up
system (Promega Madison, WI, USA).
The extracted DNA was analysed by PCR/SSCP and nucleotide
sequencing. The MGMT coding regions, exons 2–5, were amplified
by PCR with exon-specific PCR primers (Otsuka et al, 1996; Wang
et al, 1997). PCR reactions were performed on a Perkin-Elmer 9600
thermal cycler (Applied Biosystems, Foster City, CA, USA) under
the following amplification conditions: denaturation at 941C for
4min, followed by 30 cycles at 941C for 30s (35 cycles 40s for exon
4), annealing for exons 2, 3 and 5 at 66, 60, and 67 for 30s,
respectively (exon 4 at 551C for 50s), and 721C for 30s (exon 4 for
60s), and then a 7-min extension. The PCR products were 210, 201,
184 and 295bp, respectively. The PCR product of exon 5 was
cleaved with SacI before electrophoresis for optimal resolution on
the SSCP gel. The PCR products, labelled by incorporation of
[a-
32P]dCTP, were denatured in denaturing buffer at 921C for
10min, followed by SSCP analysis carried out on 7.5% non-
denaturing polyacrylamide gels in the presence of 10% glycerol at
141C (exon 4), 181C (exon 2) or 251C (exon 3) and in the absence
of glycerol at 181C (exon 5). Finally, the dried gels were exposed to
X-ray film. Samples that showed a motility shift pattern in the
SSCP films were always subjected to a reanalysis starting from PCR
amplification. Only those samples showing reproducible altera-
tions were subjected to DNA sequencing.
Nucleotide sequencing was performed in both directions with
the same primers as used in PCR using the Big Dye terminator
method and an ABI 310 genetic analyzer (Applied Biosystems).
In vitro mutagenesis in E. coli and analyses of protein
expression and DNA repair activity
MGMT expressed in plasmid Bluescript II KSþ (pBS) was used for
construction of MGMT variant isoleucine 143 to valine (I143V)
and combined with variant lysine 178 to arginine (K178R), and the
MGMT constructs expressed in plasmid pUC-18 was used in
studies of MGMT expression and DNA repair activity in E. coli. E.
coli mutant strain GWR111 (Dada-25::Cam
r, Dogt-1:: Kan
r) was
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pUC-MGMT cDNA constructs.
MGMT variants I143V and I143V/K178R were generated using
the PCR-based overlap extension technique (Ho et al, 1989). To
construct these variants, primers were designed as primer A (50-
AATCCGGTACCCATCCTCGTCCCGT-30) and primer B (50-
ATGGGTACCGGATTGCCTCT-30) for variant I143V, and primer
C( 5 0-TTGGGGAGGCCTGGCTTGG-30) and primer D (50-
TCCCTCCCAAGCCAGGCCT-30) for variant K178R (mismatches
underlined and Asp718 and StuI sites shown in italics). To generate
MGMT variant I143V, the PCR reaction was carried out using Pfu
polymerase (Stratagene La Jolle, CA, USA) with pBS-MGMT
plasmid as template and A and T7 or B and T3 as primers,
respectively, under the following conditions: 30 cycles of
denaturation for 45s at 941C, annealing for 45s at 551C, extension
for 1min at 721C. The two halves of the cDNA were joined in a
second PCR with T7 and T3 as primers. This second PCR was
performed under the same conditions as described for the primary
PCR. MGMT variant I143V/K178R was generated in the same
manner except using pBS-MGMT I143V as template and primers C
and D instead of primers A and B. The PCR product (B1kb) was
gel-purified (Geneclean II: Bio101, La Jolla, CA, USA), digested by
EcoRI (Roche Diagnostics Scand AB, Stockholm, Sweden),
repurified and then ligated into the linearised and dephosphory-
lated vector pUC-18 to get the constructs pUC-MGMT variants
I143V, I143V/K178R and MGMT wild-type, respectively. These
constructs were introduced into E. coli strain GWR111 by chemical
transformation. After selection of the white clones containing
recombinant MGMT cDNA by a-complementation with X-gal and
IPTG, plasmid DNA was isolated by JET quick plasmid miniprep
kit (Genomed GmbH, Germany), and digested by either EcoRI and
Asp718 or EcoRI and StuI (Roche) to verify that the selected clones
contained the constructs pUC-MGMT I143V and pUC-MGMT
I143V/K178R, respectively. The selected plasmid DNA was
digested by SacI to select the subclone in the right insert direction,
and was then sequenced to confirm the right insertions without
any secondary variants.
Crude cell extracts for the MGMT expression and DNA repair
activity analyses were prepared from different transformed E. coli
grown to OD
600 0.6–0.8 in 2ml LB medium with 50mgml
 1
ampicillin and 50mgml
 1 kanamycin by sonicating the bacterial
pellet resuspended in TE buffer with 100mgml
 1 lysozyme and 1%
Triton X-100 at 371C for 10min. Cell debris was pelleted and the
supernatant was used to determine MGMT expression and DNA
repair activity in E. coli. Protein amount in cell extracts was
determined with Bio-Rad’s protein assay using a BioSpec-1601E
protein analyser (Shimadzu, Japan).
Studies of expression of I143V and I143V/K178R variant MGMT
proteins was performed by Western blot analyses. Cell extract
proteins (4mg) were resolved by 12% polyacrylamide–SDS gel
electrophoresis along with a Rainbowt coloured protein molecular
weight marker (Amersham Pharmacia Biotech AB, Uppsala,
Sweden) and transferred onto a polyvinylidene difluoride mem-
brane for Western blotting. The clone MT3.1 monoclonal MGMT
antibody was used at the concentration of 1mgml
 1 (1:1000).
HRP-conjugated anti-mouse antibody (Rockland, PA, USA) was
incubated at a concentration of 1:10000. The membrane was
developed with SuperSignal West Pico chemiluminescence sub-
strate (Pierce, Rockford, IL, USA) and exposed to X-ray film. O
6-
methylguanine-DNA-methyltransferase expression was quantified
by a MultiImager (BioRad Hercules, CA, USA).
The MGMT activity analyses were performed as described
previously (Wu et al, 1987; Kreklau et al, 1999) with some
modification. Briefly, an 18-bp oligomer was synthesised to
contain the O
6-mG lesion within a PvuII restriction site. This
oligo was radiolabelled by filling in the 30 recessed end of the
complementary 16-bp strand with [a-
32P] dTTP, followed by
purification with QIAquick nucleotide removal kit (Qiagen GmbH,
Hilden, Germany) to remove the incorporated radioactive probe.
O
6-methylguanine-DNA-methyltransferase activity was measured
by incubating 0.2pmol of the radiolabelled probe with 1 and 5mg
of cell extract protein at 371C for 2h. The probe was then digested
with PvuII (Roche) and electrophoresed on a 20% denaturing
polyacrylamide gel. Results were quantified on a MultiImager.
MGMT activity is proportional to the amount of radiolabelled 8-bp
fragment produced.
For the N-methyl-N0-nitro-N-nitrosoguanidine (MNNG) survival
assay, GWR111-containing plasmids expressing MGMT wild-type,
variants I143V, I143V/K178R or empty vector were grown in LB
medium containing 50mgml
 1 ampicillin and 50mgml
 1 kanamy-
cin with agitation at 371C until the OD
600 was 0.7. The cultures
were then pelleted, washed, resuspended in LB medium and
exposed to MNNG (0–40mgml
 1) for 20min. The reactions were
stopped by diluting small aliquots of bacterial cultures in LB
medium on ice. The bacteria were further diluted and spread on LB
plates containing the same antibiotics as in culture. The plates
were incubated at 371C for 16h, and the numbers of colonies were
counted. The percentage of survival was determined by calculating
the ratios of colony numbers in cultures exposed to MNNG and
those in cultures without treatment.
RESULTS
Analysis of MGMT expression in biopsies of melanoma metastases
was performed by immunohistochemistry using the MT 3.1
monoclonal human anti-MGMT antibody. O
6-methylguanine-
DNA-methyltransferase expression varied considerably between
tumours from different melanoma patients and also among
different metastases from the same patient, ranging from
completely negative to 100% positive staining. Among all 79
patients, 65 of whom were included in our earlier study (Ma et al,
2002), there were nine responders (41%) in 22 patients with
tumours with low MGMT expression, while there were 11
responders (19%) in 57 patients carrying tumours with high
expression of MGMT. This difference in response rate is
statistically significant (P¼0.05, w
2 test, Table 1a). Among 53
patients treated with DTIC alone, there was a similar tendency of
improved clinical response in patients whose tumours had low
MGMT expression. However, this difference was not significant
(P¼0.09, w
2 test, Table 1b), possibly due to the low number of
patients treated with DTIC alone. Of the 79 patients analysed, nine
obtained CR following chemotherapy. Of these, six had low MGMT
expression (o50%). However, among the six CRs to single-agent
DTIC therapy three patients had tumours with high MGMT protein
levels (X50%), indicating that other factors than MGMT may
Table 1 MGMT expression and clinical response to DTIC-based
chemotherapy in 79 patients with metastatic melanoma
MGMT-positive cells
Response to chemotherapy o50% X50%
All patients (n¼79) (P¼0.05
(w
2 test))
Responders (n¼20) 9 (41%) 11 (19%)
Nonresponders (n¼59) 13 (59%) 46 (81%)
Response to DTIC MGMT-positive cells
o50% X50%
Patients treated with DTIC only (n¼53)
(P¼0.09 (w
2 test))
Responders (n¼12) 5 (42%) 7 (17%)
Nonresponders (n¼41) 7 (58%) 34 (83%)
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sinfluence clinical response. In 20 of the patients more than one
metastasis was analysed, and in nine of these cases the MGMT
expression differed between tumours in the same individual
according to the 50% cutoff level.
Single nucleotide polymorphisms in the coding regions of the
MGMT gene, exons 2–5, were investigated in DNA extracts from
melanoma metastases by PCR/SSCP and nucleotide sequencing.
The variants were found in exons 3 and 5 of the MGMT gene
(Table 2). SSCP analysis of exon 3 of the MGMT gene revealed two
band shift patterns: wt/53/84 and wt/84. The codon 53 variant was
a silent alteration of L (CTC) to L (CTT). The variant of codon 84
was a missense alteration that converts L (CTT) to F (TTT). These
codon 53 and 84 polymorphisms were first described in Japanese
population by Otsuka et al (1996). In most cases (eight out of
nine), the L84F and L53L were linked, although in one case only
the L84F appeared. Our SSCP analysis of exon 5 in the MGMT gene
showed a single band shift pattern: wt/143/178. The codon 143
variant was a change from I (ATC) to V (GTC), and the variant at
codon 178 was from K (AAG) to R (AGG). The polymorphisms of
codons 143 and 178 were always linked together. This finding has
also been reported by Deng et al (1999) and by us in a previous
study (Egyha ´zi et al, 2002). No polymorphisms were found in
exons 2 and 4 of the MGMT gene in our melanoma patients.
When the frequencies of MGMT SNPs in exons 3 and 5 in 52
melanoma metastases were compared to MGMT SNPs in members
of melanoma families and Swedish healthy subjects, there were no
significant differences (Table 2).
We studied the relation between MGMT SNPs and clinical
response to DTIC-based chemotherapy in 52 melanoma patients
(Table 3). In patients with the exon 3 SNPs, the response rate was
44% (four out of nine) compared to 37% (16 out of 43) in those
without these SNPs (P¼0.69). In patients with the exon 5 SNPs,
the response rate was 18% (two out of 11) compared to 44% (18
out of 41) in those without the SNPs (P¼0.10). In patients with
both exons 3 and 5 SNPs, the response rate was 29% (five out of
17) compared to 43% (15 out of 35) in those lacking either of the
SNPs (P¼0.34). There were thus no significant differences
between patients with MGMT SNPs regard to clinical response to
chemotherapy, although there was a tendency towards a lower
response rate in patients with exon 5 SNPs. We also compared
MGMT SNPs to MGMT protein expression, analysed by immuno-
histochemistry, in these 52 patients (Table 4). In patients with exon
3 SNPs, a larger proportion of tumours with high MGMT
expression was 89% (eight out of nine) compared to 67% (29
out of 43) without these SNPs (P¼0.19, Fisher’s test). A similar
proportion was shown in either exon 5 or both these exons with or
without the SNPs.
Functional analysis of variants I143V and I143V/K178R of
MGMT was performed by in vitro mutagenesis in E. coli.
Construction of MGMT variant pUC-I143V and double variant
pUC-I143V/K178R was made by the PCR-based overlap extension
technique, and these constructs were used to transform the
MGMT-deficient E. coli strain GWR 111. Analysis of MGMT
expression in E. coli was performed by Western blot with
monoclonal anti-MGMT antibody. As shown in Figure 1A, MGMT
expression was not decreased in E. coli transformed with either
variant I143V or I143V/K178R compared to wild-type MGMT.
O
6-methylguanine-DNA-methyltransferase DNA repair activity
was tested with an oligomer containing O
6-mG, which was
incubated with 1 and 5mg of cell extract protein (Figure 1B). No
reduced MGMT activity could be seen for either variant compared
with wild-type protein. In fact, a marginally increased MGMT
activity was shown for variant I143V. Analysis of MGMT function
was also performed with an MNNG survival assay (Figure 1C). The
sensitivity to MNNG in E. coli with MGMT-I143V or -I143V/K178R
was at the same level as in E. coli with MGMT wild-type. As
expected, E. coli lacking MGMT expression is considerably more
sensitive to MNNG compared to bacteria expressing wild-type or
variant MGMT.
DISCUSSION
We observed an inverse relationship between MGMT expression
and clinical response to DTIC-based chemotherapy in patients
with metastatic melanoma (P¼0.05), indicating that MGMT is a
factor that contributes to drug resistance against DTIC-based
chemotherapy in melanoma. It has been demonstrated previously
in an extensive series of preclinical and clinical studies that MGMT
is responsible for resistance to methylating agents (Pegg, 1990,
2000). A recent clinical trial showed that analysis of MGMT
expression could predict resistance to TMZ in malignant glioma
(Friedman et al, 1998b). The resistance to TMZ in renal cell cancer
may also be due to high MGMT activity since high MGMT activity
was observed in pretreatment biopsies from renal cell cancer from
four patients who showed no response to TMZ (Park et al, 2002).
Table 2 Frequency of MGMT SNPs in patients with metastatic melanoma compared with the results of our earlier study of familial melanoma and
Swedish healthy subjects
Gene
region Nucleotide alteration Coding effect
Functional effect
in vitro
Metastatic melanoma
(n¼52)
Familial melanoma
(n¼89)
Healthy subjects
(n¼76)
Exon 3 Codon 53 CTC4CTT Leu 4Leu silent None (?) 8 (15%) 17 (19%) 16 (21%)
Codon 84 CTT4TTT Leu 4Phe None (Inoue, 2000) 9 (17%) 20 (23%) 19 (25%)
Exon 5 Codon 143 ATC4GTC Ile 4Val None (this study) 11 (21%) 21 (24%) 17 (22%)
Codon 178 AAG4AGG Lys 4Arg None (this study) 11 (21%) 21 (24%) 17 (22%)
Table 3 Frequency of MGMT SNPs and clinical response to DTIC-based
chemotherapy in 52 patients with metastatic melanoma
MGMT SNPs
Response to chemotherapy Exon 3 Exon 5 Exon 3 and/or 5
Responders (n¼20) 4 (44%) 2 (18%) 5 (29%)
Nonresponders (n¼32) 5 (56%) 9 (82%) 12 (71%)
Table 4 MGMT SNPs and its expression by immunohistochemistry in 52
patients with metastatic melanoma
MGMT SNPs
MGMT
Exon 3 Exon 5 Exon 3 and/or 5
expression SNPs+ SNPs  SNPs+ SNPs  SNPs+ SNPs 
o50% 1 (11%) 14 (33%) 4 (36%) 12 (29%) 4 (24%) 11 (31%)
X50% 8 (89%) 29 (67%) 7 (64%) 29 (71%) 13 (76%) 24 (69%)
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sIn contrast, Middleton et al (1998) found no correlation between
MGMT activity in tumour extracts and the clinical response to
TMZ in metastatic melanoma. In that investigation, the MGMT
activity measurements were performed on extracts from a single
metastasis in each patient without regard to possible tumour
heterogeneity. In fact, a marked heterogeneity of MGMT expres-
sion in melanoma tumour cells has been shown in our previous
(Egyha ´zi et al, 1997; Ma et al, 2002) and present studies. Different
metastases in the same patient also frequently expressed different
levels of MGMT, which may explain why some melanoma patients
obtain only a partial response to chemotherapy even though they
have a low MGMT expression in the excised tumours. Inter- and
intratumour heterogeneity in expression of MGMT in different
kinds of tumours seems to be common (Egyha ´zi et al, 1997;
Clemons et al, 2002; Lees et al, 2002; Ma et al, 2002). The
heterogeneity between and within tumours from the same patient
may be due to tumour cell subpopulations with differences in
MGMT expression, possibly related to heterogeneity in MGMT
promoter methylation. The variability in MGMT expression
showed no correlation to proliferation when expression of Ki67
was analysed (Egyha ´zi et al, 1997). Further investigations are
required to clarify the causes of MGMT heterogeneity.
Some of our melanoma patients had been treated with
combination chemotherapy of DTIC–vindesine–cisplatin, which
complicates the evaluation. Cisplatin has been shown to decrease
MGMT activity in a time- and dose-dependent manner in a human
leukaemic cell line, and combination of TMZ and cisplatin caused
substantial and prolonged MGMT depletion, suggesting that TMZ
and cisplatin in combination may improve the clinical efficacy
(D’Atri et al, 2000).
Recent reports have given insights into the complex mechanisms
of regulation of MGMT expression. There are several different
factors of importance for regulation of MGMT expression. p53
accumulation results in loss of MGMT mRNA and protein, due to a
reduction in the rate of MGMT gene transcription. Thus, p53 is a
negative regulator of MGMT gene expression which can create an
MGMT-depleted state in human tumours (Srivenugopal et al,
2001). Expression of wild-type p53 was associated with low MGMT
level in primary ovarian cancer, supporting the view that
downregulation of basal MGMT promoter activity by p53 wild
type is also relevant in tumour cells in vivo (Hengstler et al, 1999).
However, in another study p53 has been shown to upregulate the
MGMT expression (Rafferty et al, 1996). Other factors, such as a
tyrosine kinase and a serine/threonine kinase phosphorylate the
MGMT protein and thereby affect its function (Mullapudi et al,
2000). Histone acetylation also regulates MGMT expression
(Bhakat and Mitra, 2000). Besides that, the methylation status of
the MGMT gene has been demonstrated to have an impact on drug
response. Acquired resistance to the chloroethylating antineoplas-
tic agent fotemustine in melanoma cells is caused by reactivation
of the DNA repair gene MGMT, which is associated with
hypermethylation of the body of the gene (Christmann et al,
2001). In our study, all except one of the melanoma patients
with the 53/84 polymorphism in exon 3 had tumours with high
MGMT expression. One possible hypothesis explaining this
phenomenon is that the methylation pattern in the body of the
MGMT gene may be increased by these SNPs. Conversely,
inactivation of MGMT by methylation of the promoter has been
associated with clinical response of gliomas to alkylating agents
(Esteller et al, 2000).
We also investigated polymorphisms of the MGMT gene in
patients with metastatic melanoma in order to explore the possible
role of these polymorphisms in DTIC-based chemotherapy. From
our clinical data, there was no significant correlation between
polymorphisms in exons 3, 5 or both and clinical response to
DTIC-based chemotherapy. However, an indication was obtained
of poorer response in patients with SNPs in exon 5, which fits well
with the tendency to an increased MGMT activity in E. coli
transformed with the exon 5 I143V variant. Thus, MGMT
expression seems to be more relevant for response to chemother-
apy than these MGMT SNPs. The SNPs in the MGMT gene
identified in these melanoma patients are heterozygous; thus the
wild-type allele is always present. It is therefore of interest to study
whether the gene variant is expressed in those tumours, to be able
to draw definite conclusions regarding its effect on protein activity.
These polymorphisms identified in our melanoma patients may
affect MGMT function differently. We have assumed that the
codon 53 silent polymorphism has no effect on MGMT activity, but
this may be wrong. As mentioned before, this SNP might possibly
have an effect on the methylation status of the MGMT gene and
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Figure 1 (A) Expression of variant MGMT protein in GWR111 cells.
Extracts from GWR111 cells expressing wild type, its variants I143V, I143V/
K178R or vector control were resolved by SDS–PAGE, transferred to
membrane and developed using human anti-MGMT monoclonal antibody.
(B) MGMT activity in GWR111 cells using
32P-labelled oligonucleotide.
Extracts from GWR111 cells expressing vector control, wild type, its
variants I143V or I143V/K178R were incubated with
32P-labelled
oligonucleotide and cleaved with PvuII. A measure of 1 or 5mg of protein
were incubated. (C) The effects of variants I143V and I143V7K178R on the
survival of MNNG-treated GWR111 cells. The survival of GWR111 cells
expressing MGMT is shown after treatment with MNNG concentration.
Results are shown for cells expressing wild-type MGMT (’), variant I143V
(m), I143V/K178R (K), and vector control (&).
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codon 84 polymorphism of the MGMT gene present in Swedish
individuals (Egyha ´zi et al, 2002), and also seen in Japanese (Otsuka
et al, 1996), Chinese and other Caucasian populations (Deng et al,
1999), has no defect MGMT function (Inoue et al, 2000). The
codon 178 polymorphism is unlikely to affect MGMT activity since
MGMT can be truncated at position 176 with no loss of activity,
but this SNP may still affect the protein’s stability (Hazra et al,
1997). Codon 143 is very close to the active site cysteine-145 of
MGMT, and thus the codon 143 SNP could have an effect on
MGMT activity. We therefore performed a functional analysis by
in vitro mutagenesis in E. coli to investigate whether the MGMT
I143V or I143V/K178R variants could have an effect on MGMT
activity. E. coli strain GWR111 carrying variant MGMT I143V or
double variant I143V/K178R exhibited almost the same identical
sensitivity against MNNG as did GWR111 with wild-type MGMT,
and assays of MGMT expression and MGMT activity showed no
decrease compared to the wild-type protein. No evidence was
shown that variants MGMT I143V and I143V/K178R have a
negative effect on the MGMT activity in E. coli.
Our data indicate that MGMT expression had a significant
correlation to clinical response, suggesting that MGMT may be an
important drug resistance factor against DTIC-based chemother-
apy in patients with metastatic melanoma. O
6-methylguanine-
DNA-methyltransferase may thus be used as a target to sensitise
tumour cells to improve the clinical efficacy in patients with
chemotherapy-resistant tumours. Inhibitors of MGMT activity,
such as O
6-BG are now investigated in clinical trials. Phase I
studies of O
6-BG have already been carried out with the aim of
modulating MGMT activity and thereby circumventing drug
resistance in the clinic (Friedman et al, 1998a; Friedman et al,
2000; Schilsky et al, 2000). A phase II trial of O
6-BG plus BCNU for
chemotherapy-resistant tumours has been conducted and none of
the 18 participating patients showed any response although stable
disease was seen in five patients (Quinn et al, 2002). Another
MGMT inhibitor, O
6-4-bromothenyl-guanine (4BTG) enhanced the
antitumour effect of TMZ in human melanoma xenografts
(Middleton et al, 2000). The use of such inhibitors may help to
determine the role of MGMT in resistance to DTIC-based
chemotherapy and may be used to improve the clinical results in
treatment of malignant melanoma. A future approach to treatment
of tumours with high expression of MGMT may consist of
depletion of tumour MGMT with O
6-BG and protection of sensitive
bone marrow cells, using genetic modification with O
6-BG-
resistant MGMT mutants, such as P140K and G156A. P140K
MGMT gene transfer in a murine model indicates significant
resistance to the myelosuppressive effects of TMZ and O
6-BG
(Sawai et al, 2001), and P140A MGMT protects haematopoietic
cells against O
6-BG sensitisation to chloroethylnitrosourea treat-
ment (Maze et al, 1999). G156A MGMT mutant cDNA has been
transducted into haematopoietic progenitors, resulting in remark-
able resistance to O
6-BG and BCNU (Davis et al, 1997). A clinical
trial involving transduction of G156A MGMT into CD34þ cells of
patients with cancer has been approved (Koc et al, 1999).
In conclusion, we found a significant relationship between
MGMT expression and clinical response to DTIC-based che-
motherapy. Owing to tumour heterogeneity, a possible future
strategy to obtain a more correct evaluation of MGMT levels in
relation to clinical response to DTIC-based treatment is to analyse
multiple tumours in patients using fine-needle biopsies. This could
help to determine to what extent MGMT has a clinical impact as a
drug resistance factor in malignant melanoma. The fact that only
50% of the responders with single-agent DTIC therapy had
tumours with o50% MGMT-positive tumour cells, indicates that
other additional factors are involved in response to chemotherapy
in these melanoma patients. Analysis of a panel of multiple
potential factors should be performed by gene expression profiling
in melanoma patients to find new potential factors related to
resistance or sensitivity to chemotherapy.
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